Clinical significance of amphiregulin in patients with chronic kidney disease.
Amphiregulin
Biomarker
Chronic kidney disease
EGFR
Fibrosis
Renal prognosis
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
25 Feb 2024
25 Feb 2024
Historique:
received:
26
05
2023
accepted:
02
12
2023
medline:
25
2
2024
pubmed:
25
2
2024
entrez:
25
2
2024
Statut:
aheadofprint
Résumé
Amphiregulin (AREG) is a ligand of epidermal growth factor receptor (EGFR), which plays an important role in injury-induced kidney fibrosis. However, the clinical significance of serum soluble AREG in chronic kidney disease (CKD) is unclear. In this study, we elucidated the clinical significance of serum soluble AREG in CKD by analyzing the association of serum soluble AREG levels with renal function and other clinical parameters in patients with CKD. In total, 418 Japanese patients with CKD were enrolled, and serum samples were collected for the determination of soluble AREG and creatinine (Cr) levels, and other clinical parameters. Additionally, these parameters were evaluated after 2 and 3 years. Moreover, immunohistochemical assay was performed ate AREG expression in the kidney tissues of patients with CKD. Soluble AREG levels were positively correlated with serum Cr (p < 0.0001). Notably, initial AREG levels were positively correlated with changes in renal function (ΔCr) after 2 (p < 0.0001) and 3 years (P = 0.048). Additionally, soluble AREG levels were significantly higher (p < 0.05) in patients with diabetic nephropathy or primary hypertension. Moreover, AREG was highly expressed in renal tubular cells in patients with advanced CKD, but only weakly expressed in patients with preserved renal function. Serum soluble AREG levels were significantly correlated with renal function, and changes in renal function after 2 and 3 years, indicating that serum soluble AREG levels might serve as a biomarker of renal function and renal prognosis in CKD.
Sections du résumé
BACKGROUND
BACKGROUND
Amphiregulin (AREG) is a ligand of epidermal growth factor receptor (EGFR), which plays an important role in injury-induced kidney fibrosis. However, the clinical significance of serum soluble AREG in chronic kidney disease (CKD) is unclear. In this study, we elucidated the clinical significance of serum soluble AREG in CKD by analyzing the association of serum soluble AREG levels with renal function and other clinical parameters in patients with CKD.
METHODS
METHODS
In total, 418 Japanese patients with CKD were enrolled, and serum samples were collected for the determination of soluble AREG and creatinine (Cr) levels, and other clinical parameters. Additionally, these parameters were evaluated after 2 and 3 years. Moreover, immunohistochemical assay was performed ate AREG expression in the kidney tissues of patients with CKD.
RESULTS
RESULTS
Soluble AREG levels were positively correlated with serum Cr (p < 0.0001). Notably, initial AREG levels were positively correlated with changes in renal function (ΔCr) after 2 (p < 0.0001) and 3 years (P = 0.048). Additionally, soluble AREG levels were significantly higher (p < 0.05) in patients with diabetic nephropathy or primary hypertension. Moreover, AREG was highly expressed in renal tubular cells in patients with advanced CKD, but only weakly expressed in patients with preserved renal function.
CONCLUSION
CONCLUSIONS
Serum soluble AREG levels were significantly correlated with renal function, and changes in renal function after 2 and 3 years, indicating that serum soluble AREG levels might serve as a biomarker of renal function and renal prognosis in CKD.
Identifiants
pubmed: 38402497
doi: 10.1007/s10157-023-02445-8
pii: 10.1007/s10157-023-02445-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.
Références
Bohle A, Müller GA, Wehrmann M, Mackensen-Haen S, Xiao JC. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int Suppl. 1996;54:S2-9.
pubmed: 8731185
Bullen AL, Katz R, Jotwani V, Garimella PS, Lee AK, Estrella MM, et al. Biomarkers of kidney tubule health, CKD progression, and acute kidney injury in SPRINT (Systolic Blood Pressure Intervention Trial) participants. Am J Kidney Dis. 2021;78:361-8.e1.
doi: 10.1053/j.ajkd.2021.01.021
pubmed: 33857535
pmcid: 8384678
Singh SS, Chauhan SB, Kumar A, Kumar S, Engwerda CR, Sundar S, et al. Amphiregulin in cellular physiology, health, and disease: potential use as a biomarker and therapeutic target. J Cell Physiol. 2022;237:1143–56.
doi: 10.1002/jcp.30615
pubmed: 34698381
Zaiss DMW. Amphiregulin as a driver of tissue fibrosis. Am J Transplant. 2020;20:631–2.
doi: 10.1111/ajt.15743
pubmed: 31833651
Kefaloyianni E, Raja MR, Schumacher J, Muthu ML, Krishnadoss V, Waikar SS, et al. Proximal tubule-derived amphiregulin amplifies and integrates profibrotic EGF receptor signals in kidney fibrosis. J Am Soc Nephrol. 2019;30:2370–83.
doi: 10.1681/ASN.2019030321
pubmed: 31676723
pmcid: 6900800
Kefaloyianni E, Muthu ML, Kaeppler J, Sun X, Sabbisetti V, Chalaris A, et al. ADAM17 substrate release in proximal tubule drives kidney fibrosis. JCI Insight. 2016;1: e87023.
doi: 10.1172/jci.insight.87023
pubmed: 27642633
pmcid: 5026414
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
doi: 10.1053/j.ajkd.2008.12.034
pubmed: 19339088
Melderis S, Hagenstein J, Warkotsch MT, Dang J, Herrnstadt GR, Niehus CB, et al. Amphiregulin Aggravates Glomerulonephritis via Recruitment and Activation of Myeloid Cells. J Am Soc Nephrol. 2020;31:1996–2012.
doi: 10.1681/ASN.2019111215
pubmed: 32616537
pmcid: 7461677
Palau V, Riera M, Duran X, Valdivielso JM, Betriu A, Fernández E, et al. Circulating ADAMs are associated with renal and cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2020;35:130–8.
doi: 10.1093/ndt/gfz110
pubmed: 30102333
Melderis S, Warkotsch MT, Dang J, Hagenstein J, Ehnold LI, Herrnstadt GR, et al. The Amphiregulin/EGFR axis protects from lupus nephritis via downregulation of pathogenic CD4+ T helper cell responses. J Autoimmun. 2022;129: 102829.
doi: 10.1016/j.jaut.2022.102829
pubmed: 35468361
Hanata N, Nagafuchi Y, Sugimori Y, Kobayashi S, Tsuchida Y, Iwasaki Y, et al. Serum amphiregulin and heparin-binding epidermal growth factor as biomarkers in patients with idiopathic inflammatory myopathy. J Clin Med. 2021;10:3730.
doi: 10.3390/jcm10163730
pubmed: 34442026
pmcid: 8396848
Chayangsu C, Khunsri S, Sriuranpong V, Tanasanvimon S. The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer. J Gastrointest Oncol. 2017;8:980–4.
doi: 10.21037/jgo.2017.08.15
pubmed: 29299357
pmcid: 5750193
Schramm F, Schaefer L, Wygrecka M. EGFR signaling in lung fibrosis. Cells. 2022;11:986.
doi: 10.3390/cells11060986
pubmed: 35326439
pmcid: 8947373
Zhang MY, Fang S, Gao H, Zhang X, Gu D, Liu Y, et al. A critical role of AREG for bleomycin-induced skin fibrosis. Cell Biosci. 2021;11:40.
doi: 10.1186/s13578-021-00553-0
pubmed: 33622407
pmcid: 7903615
Perugorria MJ, Latasa MU, Nicou A, Cartagena-Lirola H, Castillo J, Goñi S, et al. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology. 2008;48:1251–61.
doi: 10.1002/hep.22437
pubmed: 18634036
Todd JL, Kelly FL, Nagler A, Banner K, Pavlisko EN, Belperio JA, et al. Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation. Am J Transpl. 2020;20:825–33.
doi: 10.1111/ajt.15667
Lisi S, Sisto M, Lofrumento DD, Cucci L, Frassanito MA, Mitolo V, et al. Pro-inflammatory role of Anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun. 2010;35:160–70.
doi: 10.1016/j.jaut.2010.06.020
pubmed: 20673622
Geesala R, Issuree PD, Maretzky T. The role of iRhom2 in metabolic and cardiovascular-related disorders. Front Cardiovasc Med. 2020;7: 612808.
doi: 10.3389/fcvm.2020.612808
pubmed: 33330676
pmcid: 7732453
Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42:216–26.
doi: 10.1016/j.immuni.2015.01.020
pubmed: 25692699
pmcid: 4792035
Seung SS, Hwang S, Park JH, Ko Y, Yun SI, Lee JH, et al. In vivo silencing of amphiregulin by a novel effective Self-Assembled-Micelle inhibitory RNA ameliorates renal fibrosis via inhibition of EGFR signals. Sci Rep. 2021;11:2191.
doi: 10.1038/s41598-021-81726-2
Tang J, Liu N, Zhuang S. Role of epidermal growth factor receptor in acute and chronic kidney injury. Kidney Int. 2013;83:804–10.
doi: 10.1038/ki.2012.435
pubmed: 23325080
pmcid: 4626012
Overstreet JM, Wang Y, Wang X, Niu A, Gewin LS, Yao B, et al. Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis. FASEB J. 2017;31:4407–21.
doi: 10.1096/fj.201601359RR
pubmed: 28626027
pmcid: 5602893
Zhou Y, Lee JY, Lee CM, Cho WK, Kang MJ, Koff JL, et al. Amphiregulin, an epidermal growth factor receptor ligand, plays an essential role in the pathogenesis of transforming growth factor-β-induced pulmonary fibrosis. J Biol Chem. 2012;287:41991–2000.
doi: 10.1074/jbc.M112.356824
pubmed: 23086930
pmcid: 3516745
Morimoto Y, Hirahara K, Kiuchi M, Wada T, Ichikawa T, Kanno T, et al. Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis. Immunity. 2018;49:134-50.e6.
doi: 10.1016/j.immuni.2018.04.023
pubmed: 29958800
Makki N, Thiel KW, Miller FJ Jr. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci. 2013;14:20597–613.
doi: 10.3390/ijms141020597
pubmed: 24132149
pmcid: 3821633
Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167–76.
doi: 10.1016/j.yjmcc.2013.11.017
pubmed: 24332999
Chen J, Wang X, He Q, Bulus N, Fogo AB, Zhang MZ, et al. YAP activation in renal proximal tubule cells drives diabetic renal interstitial fibrogenesis. Diabetes. 2020;69:2446–57.
doi: 10.2337/db20-0579
pubmed: 32843569
pmcid: 7576565
Chen J, Harris RC. Interaction of the EGF receptor and the Hippo pathway in the diabetic kidney. J Am Soc Nephrol. 2016;27:1689–700.
doi: 10.1681/ASN.2015040415
pubmed: 26453611
Zaiss DM, van Loosdregt J, Gorlani A, Bekker CP, Gröne A, Sibilia M, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity. 2013;38:275–84.
doi: 10.1016/j.immuni.2012.09.023
pubmed: 23333074
pmcid: 3582723
Zaiss DM, Yang L, Shah PR, Kobie JJ, Urban JF, Mosmann TR. Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. Science. 2006;314:1746.
doi: 10.1126/science.1133715
pubmed: 17170297